Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa

Reuters

Oct 10

Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa

PegBio Co., Ltd. announced that it has entered into a non-binding term sheet with PDC FZ-LLC of the United Arab Emirates for the proposed grant of an exclusive license for Visepegenatide (PB-119), a subcutaneous injectable GLP-1 agonist for the treatment of Type II Diabetes Mellitus and obesity management. Under the proposed terms, PDC will receive exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa. The agreement is positioned as part of PegBio's global commercialization strategy for PB-119. The company noted that there is no guarantee that PB-119 will ultimately be successfully developed and marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574262241"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574262241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574262241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574262241","market":"nz","top_or_hot":-1,"title":"Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PegBio Co., Ltd. announced that it has entered into a non-binding term sheet with PDC FZ-LLC of the United Arab Emirates for the proposed grant of an exclusive license for Visepegenatide (PB-119), a subcutaneous injectable GLP-1 agonist for the treatment of Type II Diabetes Mellitus and obesity management. Under the proposed terms, PDC will receive exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa. The agreement is positioned as part of PegBio's global commercialization strategy for PB-119. The company noted that there is no guarantee that PB-119 will ultimately be successfully developed and marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-10 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PegBio Co., Ltd. announced that it has entered into a non-binding term sheet with PDC FZ-LLC of the United Arab Emirates for the proposed grant of an exclusive license for Visepegenatide (PB-119), a subcutaneous injectable GLP-1 agonist for the treatment of Type II Diabetes Mellitus and obesity management. Under the proposed terms, PDC will receive exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa. The agreement is positioned as part of PegBio's global commercialization strategy for PB-119. The company noted that there is no guarantee that PB-119 will ultimately be successfully developed and marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5n6V4C:1","article_id":"2574262241","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574262241","pubTimestamp":1760086998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PegBio Co., Ltd. announced that it has entered into a non-binding term sheet with PDC FZ-LLC of the United Arab Emirates for the proposed grant of an exclusive license for Visepegenatide , a subcutaneous injectable GLP-1 agonist for the treatment of Type II Diabetes Mellitus and obesity management. Under the proposed terms, PDC will receive exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa. The agreement is positioned as part of PegBio's global commercialization strategy for PB-119. The company noted that there is no guarantee that PB-119 will ultimately be successfully developed and marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B","BK1161":"生物科技"},"translate_title":"Pegbio Co Ltd宣布拟议的Visepegenatide PB119在中东和非洲的独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":0.9},"content_text":"Pegbio Co Ltd Announces Proposed Exclusive License Agreement for Visepegenatide PB119 in Middle East and Africa\n    \n\n        PegBio Co., Ltd. announced that it has entered into a non-binding term sheet with PDC FZ-LLC of the United Arab Emirates for the proposed grant of an exclusive license for Visepegenatide (PB-119), a subcutaneous injectable GLP-1 agonist for the treatment of Type II Diabetes Mellitus and obesity management. Under the proposed terms, PDC will receive exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa. The agreement is positioned as part of PegBio's global commercialization strategy for PB-119. The company noted that there is no guarantee that PB-119 will ultimately be successfully developed and marketed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}